Array BioPharma Inc

Most Recent

  • uploads///ARRY Revenue Trend
    Company & Industry Overviews

    Array BioPharma’s Financial Performance

    The total revenues of Array BioPharma (ARRY) decreased from $39.2 million in 1Q17 to $29.7 million in 1Q18.

    By Kenneth Smith
  • uploads///ARRY
    Company & Industry Overviews

    Array BioPharma’s ARRY-382 and ARRY-797

    Array BioPharma (ARRY) completed its Phase 1b clinical trial of its investigational drug candidate ARRY-382 in combination with Merck’s (MRK) Keytruda for advanced tumor indications.

    By Kenneth Smith
  • uploads///ARRY
    Company & Industry Overviews

    Array BioPharma’s Promising Drug for Colorectal Cancer

    On January 22, 2018, Array BioPharma announced data from the BEACON CRC trial, which showed a median progression-survival rate of eight months and an overall response rate of 48%.

    By Kenneth Smith
  • uploads///ARRY binimetinib and encorafenib
    Company & Industry Overviews

    An In-Depth Look at Array BioPharma’s Pipeline of Drugs

    In March 2015, Array BioPharma (ARRY) got the development and commercialization rights for binimetinib and encorafenib under asset transfer agreements with Novartis (NVS).

    By Kenneth Smith
  • uploads///Elacestrant market opportunity
    Company & Industry Overviews

    Taking Stock of Radius Health’s Licensing Agreements

    The market has responded very positively to Radius Health’s recent performance. In the past month, Radius stock has generated a 28% return for its shareholders.

    By Kenneth Smith
  • uploads///RDUS Analysts Reco
    Company & Industry Overviews

    Analysts’ Ratings for Radius Health and Its Peers in January

    In April 2017, Radius received FDA approval for its first commercial product, Tymlos. Tymlos was approved for the treatment of postmenopausal women with osteoporosis at a high risk for fracture.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.